NeOnc reports Q1 net loss $8.8M; NEO212 Phase 1 complete, NEO100 interim data Aug 2026

NEONC TECHNOLOGIES HOLDINGS, INC.

2026-Q1 EPS reported -$0.38 vs consensus -$0.22 ▼ miss (-69.3%)

Net loss $8.8M ($0.38/diluted) vs $32.3M ($1.78) in Q1 2025; G&A down to $489K, R&D up to $1.29M.
Cash $138,601 at Mar 31; $10M PIPE from Cinctive Capital and $10M undrawn credit line fund ops into Sep 2026.
NEO212 Phase 1 complete, RP2D set at 610 mg; FDA End-of-Phase 1 meeting planned for potential registrational Phase 2.
NEO100 Phase 2a fully enrolled in IDH1-mutant high-grade glioma; interim data readout expected August 2026.
Appointed David Choi as CAO; CEO Amir Heshmatpour purchased >$500k of NTHI shares in open market.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

NEONC TECHNOLOGIES HOLDINGS, INC. reported first quarter ended March 31, 2026 results: net income $8.8 million or $(0.38) per diluted share, EPS $(0.38) per diluted share.

Period: first quarter ended March 31, 2026
Net income: $8.8 million or $(0.38) per diluted share
EPS: $(0.38) per diluted share
Result: reported results

Exact text from the filing

NeOnc Provides Business Update and Reports Q1 2026 Financial Results

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

NEONC TECHNOLOGIES HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001829126-26-005421

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.